From: Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1
N = 103 patients
Histology WHO 2015
Thymoma B2/B3
18 (17%)
Thymoma B3
35 (34%)
Thymoma B3/C
4 (4%)
Thymic carcinoma
46 (45%)
Type
Biopsy
20 (19%)
Surgical resection
83 (81%)
Tumor
Initial resection
89 (86%)
Recurrence
Metastasis
10 (10%)